Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Status:
Recruiting
Trial end date:
2023-04-14
Target enrollment:
Participant gender:
Summary
This is a phase I/Ib, open label study. The escalation portion will characterize the safety
and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or
melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC. After the
determination of the MTD/RD for a particular treatment arm, dose expansion will further
assess safety, tolerability, PK/PD, and anti-tumor activity of each regimen at the MTD/RD.